Stifel downgraded Soleno Therapeutics (SLNO) to Hold from Buy with a price target of $53, down from $115, after Neurocrine (NBIX) announced a deal to acquire the company for $2.9B or $53 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics downgraded to Hold from Buy at TD Cowen
- Hold Rating on Soleno Reflects Capped Upside Under Neurocrine Takeover Agreement
- Soleno downgraded to Perform from Outperform at Oppenheimer
- Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- Neurocrine price target raised to $220 from $192 at Oppenheimer